Human Genome Sciences (HGSI) Substantial Progress Toward Commercialization
More News related to HGSI
- Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
- JPMorgan Boosts Target on Human Genome (HGSI) to $35
- Goldman Sachs Lifts Tgt on Human Genome Sciences (HGSI) to $30, Sees As Acquisition Candidate
- Human Genome (HGSI) volatility low at 73 after announcing positive data
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
More News related to NVS
- MultiVu Video Feed: BASKETBALL LEGEND KAREEM ABDUL-JABBAR ANNOUNCES HE HAS BEEN DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA; AIMS TO INSPIRE OTHERS
- Novartis (NVS) Acquires Majority Stake in Zhejiang Tianyuan Bio-Pharmaceutical for $125 Million
- Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
- D.C. Vaccine Conference Attracts Government Policy Makers and Biotech Innovators
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Human Genome Sciences, Inc. (Nasdaq: HGSI) reports substantial progress toward commercialization and announces 2009 goals at the JP Morgan Healthcare Conference.
The company said Albuferon for hepatitis C, LymphoStat-B for lupus and ABthrax for inhalation anthrax all progressing rapidly toward commercialization.
Expect major financial progress in 2009, with revenues of more than $250 million and net cash burn of less than $25 million.
Human Genome Sciences also announced that Novartis (NYSE: NVS) has initiated dosing in a Phase 2b trial that will evaluate the safety and efficacy of Albuferon administered monthly in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C.
Related Categories
FDAGuidance
Stocks Mentioned
-0.18Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
